Ping Chen^*, Qing Jin^*, Qiang Fu^*, Peidong You^*, Xi Jiang^*, Qin Yuan^*, Huifang Huang^†

Oncology Research, Vol.24, No.4, pp. 215-223, 2016, DOI:10.3727/096504016X14634208143021

Abstract This study aimed to investigate the role of the PI3K/Akt signaling pathway in multidrug resistance of acute myeloid leukemia (AML) cells induced by cocultured stromal cells. Human AML cell lines HL-60 and U937 were adhesion cocultured with human bone marrow stromal cell line HS-5 cells. Such coculturing induced HL-60 and U937 cells resistant to chemotherapeutic drugs including daunorubicin (DNR), homoharringtonine (HHT), and cytosine arabinoside (Ara-C). The coculturing-induced resistance of AML cells to DNR, HHT, and Ara-C can be partially reversed by inhibition of the PI3K/Akt signaling pathway. Clinically, AML patients with a low level of More >

Gangcan Li, Yanping Song, Yunjie Zhang, Hao Wang, Jia Xie

Oncology Research, Vol.24, No.2, pp. 109-116, 2016, DOI:10.3727/096504016X14611963142254

Abstract Acute myeloid leukemia (AML) is the most lethal hematological malignancy, and the occurrence of chemoresistance prevents the achievement of complete remission following the standard therapy. MicroRNAs have been extensively investigated as critical regulators of hematopoiesis and leukemogenesis, and they represent a promising strategy for AML therapy. In this study, we identified miR-34b as a novel regulator in myeloid proliferation and apoptosis of leukemic cells. We found that miR-34b was developmentally upregulated in plasma and myeloid cells of healthy subjects, while it was significantly reduced in blood samples of patients with AML and AML cell lines.… More >

Annie Im, Ali Amjad, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Seah Lim, Alison Sehgal, Kathleen A. Dorritie, Robert L. Redner, Brian McLaughlin, Yongli Shuai, Shrina Duggal, Michael Boyiadzis

Oncology Research, Vol.24, No.2, pp. 73-80, 2016, DOI:10.3727/096504016X14586627440156

Abstract Relapsed acute myeloid leukemia (AML) represents a major therapeutic challenge. Achieving complete remission (CR) with salvage chemotherapy is the first goal of therapy for relapsed AML. However, there is no standard salvage chemotherapy. The current study evaluated outcomes and prognostic factors for achievement of CR in 91 AML patients in first relapse who were treated with the mitoxantrone–etoposide combination regimen. The overall response rate (CR and CRi) was 25%. Factors that were associated with a lower rate of CR included older age, shorter duration of first CR, low hemoglobin, and low platelet count. The median… More >

Yueli Gu^*, Jinchun Si^†, Xichun Xiao^*, Ying Tian^*, Shuo Yang^*

Oncology Research, Vol.25, No.7, pp. 1069-1079, 2017, DOI:10.3727/096504016X14829256525028

Abstract Aberrant expression of microRNA-92a (miR-92a) has been investigated in various cancers. However, the function and mechanism of miR-92a in acute myeloid leukemia (AML) remain to be elucidated. Our data showed that miR-92a was evidently downregulated and methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) was remarkably upregulated in AML cell lines HL-60 and THP-1. Dual luciferase reporter assay revealed that MTHFD2 was a direct target of miR-92a. Gain- and loss-of-function analysis demonstrated that MTHFD2 knockdown or miR-92a overexpression notably inhibited proliferation and promoted apoptosis of AML cell lines. Restoration of MTHFD2 expression reversed proliferation inhibition and apoptosis induction of More >

MONA S. ABDELLATEIF^1,*, NAGLAA M. HASSAN², MAHMOUD M. KAMEL², YOMNA M. EL-MELIGUI²

Oncology Research, Vol.32, No.3, pp. 577-584, 2024, DOI:10.32604/or.2023.043026

Abstract Background: microRNA-34a (miR-34a) had been reported to have a diagnostic role in acute myeloid leukemia (AML). However, its value in the bone marrow (BM) of AML patients, in addition to its role in response to therapy is still unclear. The current study was designed to assess the diagnostic, prognostic, and predictive significance of miR-34a in the BM of AML patients. Methods: The miR-34a was assessed in BM aspirate of 82 AML patients in relation to 12 normal control subjects using qRT-PCR. The data were assessed for correlation with the relevant clinical criteria, response to therapy,… More >

ZHANSHU LIU¹, XI HUANG^2,*

BIOCELL, Vol.47, No.3, pp. 593-605, 2023, DOI:10.32604/biocell.2023.024148

Abstract Purpose: Iron metabolism maintains the balance between iron absorption and excretion. Abnormal iron metabolism can cause numerous diseases, including tumor. This study determined the iron metabolism-related genes (IMRGs) signature that can predict the prognosis of acute myeloid leukemia (AML). The roles of these genes in the immune microenvironment were also explored. Methods: A total of 514 IMRGs were downloaded from the Molecular Characteristics Database (MSigDB). IMRGs related to AML prognosis were identified using Cox regression and LASSO analyses and were used to construct the risk score model. AML patients were stratified into high-risk groups (cluster 1)… More >

K. Venkatesh^1,*, S. Pasupathy¹, S. P. Raja²

Intelligent Automation & Soft Computing, Vol.36, No.1, pp. 543-560, 2023, DOI:10.32604/iasc.2023.030701

Abstract The evolution of bone marrow morphology is necessary in Acute Myeloid Leukemia (AML) prediction. It takes an enormous number of times to analyze with the standardization and inter-observer variability. Here, we proposed a novel AML detection model using a Deep Convolutional Neural Network (D-CNN). The proposed Faster R-CNN (Faster Region-Based CNN) models are trained with Morphological Dataset. The proposed Faster R-CNN model is trained using the augmented dataset. For overcoming the Imbalanced Data problem, data augmentation techniques are imposed. The Faster R-CNN performance was compared with existing transfer learning techniques. The results show that the More >

MESFER AL SHAHRANI^1,2,*, PRASANNA RAJAGOPALAN^1,2, MOHAMMAD ABOHASSAN¹, MOHAMMAD ALSHAHRANI¹, YASSER ALRAEY¹, REEM M. GAHTANI¹, SURESH RADHAKRISHNAN³, KHLOOD DAGREERY⁴

Oncology Research, Vol.29, No.3, pp. 149-157, 2021, DOI:10.32604/or.2022.03539

Abstract Estrogen receptor (ER) α is expressed in a subset of patient-derived acute myeloid leukemia (AML) cells, whereas Akt is predominantly expressed in most types of AML. Targeting AML with dual inhibitors is a novel approach to combat the disease. Herein, we examined a novel small molecule, 3-(4-isopropyl) benzylidene-8-ethoxy,6- methyl, chroman-4-one (SBL-060), capable of targeting AML cells by inhibiting ERα and Akt kinase. The chemical properties of SBL-060 were identified by proton nuclear magnetic resonance (¹ H-NMR), ¹³C-NMR, and mass spectroscopy. In silico docking was performed using an automated protocol with AutoDock-VINA. THP-1 and HL-60 cell lines were… More >

Zhiguo Wang^*†1, Zehui Fang^‡1, Runzhang Lu^†, Hongli Zhao^‡, Tiejun Gong^†, Dong Liu^†, Luojia Hong^‡, Jun Ma^†, Mei Zhang^*

Oncology Research, Vol.27, No.9, pp. 1035-1042, 2019, DOI:10.3727/096504019X15528367532612

Abstract Although arsenic trioxide (ATO) is a well-known antileukemic drug used for acute promyelocytic leukemia treatment, the development of ATO resistance is still a big challenge. We previously reported that microRNA- 204 (miR-204) was involved in the regulation of acute myeloid leukemia (AML) cell apoptosis, but its role in chemoresistance is poorly understood. In the present study, we showed that miR-204 was significantly increased in AML cells after ATO treatment. Interestingly, the increased miR-204 level that was negatively correlated with ATO induced the decrease in cell viability and baculoviral inhibition of apoptosis protein repeatcontaining 6 (BIRC6)… More >

Juanjuan Yao^*, Liang Zhong^†, Pengqiang Zhong^*, Dongdong Liu^†, Zhen Yuan^†, Junmei Liu^*, Shifei Yao^*, Yi Zhao^*, Min Chen^*, Lianwen Li^*, Lu Liu^†, Beizhong Liu^*†

Oncology Research, Vol.27, No.7, pp. 809-818, 2019, DOI:10.3727/096504018X15451301487729

Abstract RAS-responsive element-binding protein 1 (RREB1) is a transcription factor that is implicated in RAS signaling and multiple tumors. However, the role of RREB1 in acute myeloid leukemia has not been studied. We found that RREB1 is overexpressed in AML patients and myeloid leukemia cell lines (NB4 and HL-60), and RREB1 expression was significantly decreased during granulocytic differentiation of myeloid leukemia cells induced by all-trans retinoic acid (ATRA). Then we performed a RREB1 knockdown assay in NB4 and HL-60 cells; the results showed that knockdown of RREB1 upregulated expression of CD11b, CEBP , and microRNA-145 (miR-145), More >